Cel-Sci Corp. (NYSE: CVM) aims to find the best way to activate the immune system to fight cancer and infectious diseases. The company’s lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is currently being studied in a pivotal phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the head and neck. Additional clinical indications for Multikine that are being investigated include the treatment of cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. For more information, visit the company’s website at www.cel-sci.com